Jacobson Pharma Corporation Limited (HKG:2633)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Essential Medicines and Specialty Drugs	1.57B	1.58B	1.47B	1.27B	1.19B
Essential Medicines and Specialty Drugs Growth	-0.47%	7.43%	15.77%	6.40%	13.12%
Elimination of inter-segment revenue	-	-	-16.00K	-270.00K	-2.20M
Branded Healthcare	-	-	-	-	406.14M
Branded Healthcare Growth	-	-	-	-	-0.38%
Total	1.57B	1.58B	1.47B	1.27B	1.60B
Total Growth	-0.47%	7.43%	15.79%	-20.55%	10.35%

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Hong Kong	1.51B	1.51B	1.42B	1.22B	1.43B
Hong Kong Growth	-0.02%	6.56%	16.25%	-14.40%	8.81%
Macau	31.59M	27.63M	12.90M	21.65M	59.62M
Macau Growth	14.33%	114.14%	-40.39%	-63.69%	-4.63%
Mainland China	23.34M	34.58M	33.39M	21.05M	79.97M
Mainland China Growth	-32.49%	3.56%	58.57%	-73.67%	71.57%
Others	202.00K	99.00K	-	1.95M	14.96M
Others Growth	104.04%	-	-	-86.98%	-16.23%
Singapore	-	-	136.00K	225.00K	12.57M
Singapore Growth	-	-	-39.56%	-98.21%	103.10%
Total	1.57B	1.58B	1.47B	1.27B	1.60B
Total Growth	-0.47%	7.43%	15.79%	-20.55%	10.35%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 10, 2026

Data Sources Report a data error